Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers

Neurology

Volumn 83, Issue 8, 2014, Pages 733-742

  Gaillard, Marie Cécile ^a   Roche, Stéphane ^a   Dion, Camille ^a   Tasmadjian, Armand ^a   Bouget, Gwenaëlle ^a   Salort Campana, Emmanuelle ^a,b   Vovan, Catherine ^b   Chaix, Charlene ^b   Broucqsault, Natacha ^a   Morere, Julia ^a   Puppo, Francesca ^a   Bartoli, Marc ^a   Levy, Nicolas ^a,b   Bernard, Rafaëlle ^a,b   Attarian, Shahram ^a,b   Nguyen, Karine ^a,b   Magdinier, Frédérique ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; HETEROZYGOTE; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; PENETRANCE; PHENOTYPE; POLYMORPHIC LOCUS; CHROMOSOME 4; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; PEDIGREE; YOUNG ADULT;

ADULT; CHROMOSOMES, HUMAN, PAIR 4; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HETEROZYGOTE; HUMANS; MALE; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; PEDIGREE; PENETRANCE; PHENOTYPE; YOUNG ADULT;

EID: 84920609072     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000708     Document Type: Article

References (35)

1. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet 2013;14:204-220.
2. Cantone I, Fisher AG. Epigenetic programming and reprogramming during development. Nat Struct Mol Biol 2013;20:282-289.
3. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 2000;97:710-715.
4. Bocker MT, Hellwig I, Breiling A, Eckstein V, Ho AD, Lyko F. Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood 2011;117:e182-e189.
5. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007;1775: 138-162.
6. Bergman Y, Cedar H. DNA methylation dynamics in health and disease. Nat Struct Mol Biol 2013;20: 274-281.
7. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409: 860-921.
8. Kondo T, Bobek MP, Kuick R, et al. Whole-genome methylation scan in ICF syndrome: hypomethylation of non-satellite DNA repeats D4Z4 and NBL2. Hum Mol Genet 2000;9:597-604.
9. van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003;35:315-317.
10. Sacconi S, Camano P, de Greef JC, et al. Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity. J Med Genet 2012;49:41-46.
11. van Overveld PG, Enthoven L, Ricci E, et al. Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy. Ann Neurol 2005;58:569-576.
12. de Greef JC, Lemmers RJ, Camano P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010;75:1548-1554.
13. de Greef JC, Lemmers RJ, van Engelen BG, et al. Common epigenetic changes of D4Z4 in contractiondependent and contraction-independent FSHD. Hum Mutat 2009;30:1449-1459.
14. Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012;44:1370-1374.
15. Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R, Zatz M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2004;14:33-38.
16. Lunt PW, Jardine PE, Koch MC, et al. Correlation between fragment size at D4F104S1 and age at onset or at wheelchair use, with a possible generational effect, accounts for much phenotypic variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol Genet 1995;4:951-958.
17. Goto Y, Feil R. Genomic imprinting and its effects on genes and chromosomes in mammals. Methods Mol Biol 2004;240:53-75.
18. Sakellariou P, Kekou K, Fryssira H, et al. Mutation spectrum and phenotypic manifestation in FSHD Greek patients. Neuromuscul Disord 2012;22:339-349.
19. Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol 1996;39:744-748.
20. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5- methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-1831.
21. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-556.
22. Hartweck LM, Anderson LJ, Lemmers RJ, et al. A focal domain of extreme demethylation within D4Z4 in FSHD2. Neurology 2013;80:392-399.
23. de Greef JC, Wohlgemuth M, Chan OA, et al. Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. Neurology 2007;69:1018-1026.
24. Cross SH, Charlton JA, Nan X, Bird AP. Purification of CpG islands using a methylated DNA binding column. Nat Genet 1994;6:236-244.
25. Horard B, Eymery A, Fourel G, et al. Global analysis of DNA methylation and transcription of human repetitive sequences. Epigenetics 2009;4:339-350.
26. Ricci G, Scionti I, Sera F, et al. Large scale genotypephenotype analyses indicate that novel prognostic tools are required for families with facioscapulohumeral muscular dystrophy. Brain 2013;136:3408-3417.
27. Zatz M, Marie SK, Passos-Bueno MR, et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet 1995;56:99-105.
28. Pastorello E, Cao M, Trevisan CP. Atypical onset in a series of 122 cases with FacioScapuloHumeral Muscular Dystrophy. Clin Neurol Neurosurg 2012;114:230-234.
29. Cabianca DS, Casa V, Bodega B, et al. A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell 2012; 149:819-831.
30. Gabellini D, Green MR, Tupler R. Inappropriate gene activation in FSHD: A repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 2002;110: 339-348.
31. Doi A, Park IH, Wen B, et al. Differential methylation of tissue- And cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009;41:1350-1353.
32. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102:10604-10609.
33. Scionti I, Greco F, Ricci G, et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am J Hum Genet 2012;90:628-635.
34. Caruso N, Herberth B, Bartoli M, et al. Deregulation of the protocadherin gene FAT1 alters muscle shapes: implications for the pathogenesis of facioscapulohumeral dystrophy. PLoS Genet 2013;9:e1003550.
35. Sacconi S, Lemmers RJ, Balog J, et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet 2013;93:744-751.